Highlights

  • Pacific Edge shares surged 37.93% on 15 May 2026 following a favourable Medicare draft coverage update.
  • The draft LCD proposes Medicare coverage for Cxbladder Triage and Triage Plus.
  • The proposal establishes hematuria evaluation as a covered Medicare benefit for the first time.
  • Cxbladder Triage and Triage Plus were the only urine-based biomarkers included in the draft coding article.
  • Pacific Edge said the development may support broader adoption across commercial payers in the US.
  • Medicare coverage, if finalised, could directly apply to more than 66 million beneficiaries.

Pacific Edge Ltd (ASX:PEB) shares climbed 37.93% to AUD 0.20 during the afternoon session on 15 May 2026 after the cancer diagnostics company announced a favourable Medicare draft coverage proposal involving its Cxbladder tests. The stock has also risen 150% over the past year, with today’s sharp move appearing linked to investor optimism surrounding the potential expansion of reimbursement access for the company’s bladder cancer diagnostic products in the United States.

The company disclosed that a draft Local Coverage Determination (LCD) for urine-based biomarkers in microhematuria evaluation had been published to the Medicare Coverage Database. Importantly, the associated billing and coding guidance specifically included Cxbladder Triage and Cxbladder Triage Plus as proposed reimbursable tests under the policy framework.

According to Pacific Edge, the proposal establishes hematuria evaluation as a covered Medicare benefit for the first time and distinguishes microhematuria patients as eligible for urine biomarker testing. The company noted this differs from an existing non-coverage policy focused on patients with cancer or substantiated suspicion of cancer.

Pacific Edge is a cancer diagnostics company specialising in non-invasive genomic urine tests designed to assist with the detection and management of bladder cancer. Its Cxbladder product suite is used for risk stratification in patients presenting with hematuria as well as surveillance for recurrent disease. The company operates CLIA-certified laboratories in both New Zealand and the United States and markets its products internationally.

Draft Medicare Proposal Seen as Major Commercial Development

The draft LCD appears to represent a notable regulatory and commercial milestone for Pacific Edge’s US Business operations.

In the rationale section of the proposal, Novitas stated that limited coverage for selected urine-based biomarker testing may be considered reasonable and necessary in appropriately counselled intermediate-risk patients with microhematuria who are considering deferral of cystoscopy.

Pacific Edge highlighted that the associated draft coding article only included Cxbladder Triage and Cxbladder Triage Plus among urine-based biomarker tests. Management believes this may create a favourable competitive positioning around its microhematuria business within the proposed reimbursement framework.

The company said the draft language reflects a growing body of clinical evidence supporting the use of its products and aligns with clinical discussions held during the recent Contractor Advisory Committee meeting convened by Novitas in February 2026.

Pacific Edge Chief Executive Dr Peter Meintjes described the draft proposal as an important outcome for Medicare patients, urologists and the wider healthcare system. According to management, the decision supports access to appropriate patient care while balancing both clinical and economic considerations.

Medicare Opportunity Could Extend Beyond Public Coverage

One of the more significant aspects of the announcement relates to the broader commercial implications beyond direct Medicare reimbursement.

Pacific Edge stated that if the draft LCD is ultimately finalised, it would directly support reimbursement access for more than 66 million Medicare beneficiaries in the United States. However, management also indicated that the proposed coverage language may serve as a template for commercial insurers covering approximately 223 million additional lives across the US healthcare system.

The company noted that the draft policy may also support adoption of Cxbladder products in international markets as healthcare systems increasingly evaluate evidence-backed non-invasive diagnostics.

According to Pacific Edge, the inclusion of both Cxbladder Triage and Triage Plus in the draft coverage framework provides an opportunity to transition customers toward the newer Triage Plus product, which management says offers broader patient applicability and improved clinical Utility.

Importantly, Pacific Edge highlighted the financial implications associated with Triage Plus reimbursement. The company stated that Medicare pricing for Triage Plus stands at US$1,328 per test, compared with approximately US$760 for legacy Cxbladder products. Management said this represents a 75% improvement in reimbursement Economics.

The company also believes the reimbursement structure may assist its pathway toward operating profitability over time.

Clinical Evidence Strategy Appears to Support Policy Shift

Pacific Edge attributed the proposed Medicare coverage framework to years of evidence generation supporting the clinical validity and utility of its diagnostic products.

The company stated that its value creation strategy focuses on developing analytical validity, clinical validity and clinical utility evidence using defined patient populations and statistically significant sample sizes.

Management indicated that this evidence-driven approach has been central to influencing physician behaviour and supporting medical policy discussions.

Pacific Edge also noted that Cxbladder Triage is already included in the American Urological Association’s Microhematuria Guideline, which may further strengthen the clinical positioning of the test.

According to the company, its evidence portfolio now includes more than 25 peer-reviewed publications developed over approximately two decades of research.

The company added that it intends to continue applying this evidence-generation model to future products including Surveillance Plus and additional diagnostics beyond bladder cancer applications.

Draft Coverage Process Now Enters Public Comment Stage

While the announcement was viewed positively by the market, the Medicare proposal remains in draft form and is subject to a formal review process.

Pacific Edge explained that publication of the draft LCD begins a structured “Notice and Comment” process governed under the Medicare Program Integrity Manual.

This process includes a public meeting and a minimum 45-day comment period during which Novitas will accept written submissions from Stakeholders. Within 12 months, Novitas is expected to either finalise or withdraw the draft LCD.

If finalised, the coverage determination would become effective 45 days after publication.

Pacific Edge indicated it plans to engage with Novitas during the draft period to seek reimbursement for Triage and Triage Plus claims on a case-by-case basis.

Management also said it looks forward to Novitas addressing stakeholder comments given what it described as alignment between the draft proposal, the underlying clinical evidence and expert opinions expressed during the recent advisory committee discussions.

Retail Offer and Capital Raising Update

Alongside the Medicare update, Pacific Edge also provided details regarding its ongoing capital raising initiatives.

The company confirmed that its retail offer to eligible shareholders opened on 14 May 2026 and is scheduled to close on 28 May 2026. Under the offer, eligible shareholders in New Zealand may apply for up to NZ$50,000 worth of new shares at NZ$0.17 per share.

The retail component follows completion of a NZ$25.4 million Placement to selected investors earlier this month. Pacific Edge stated that more than 90% of the placement shares were allocated to existing shareholders.

Management noted that the retail offer and placement were both conducted at the same issue price.

Cxbladder Continues Expanding International Presence

Pacific Edge’s Cxbladder tests are currently available across the United States, Australasia, Israel and selected markets throughout Asia and South America.

In the US alone, the company stated that more than 5,000 urologists have ordered over 130,000 Cxbladder tests to date.

Within New Zealand, approximately 70% of the population can access Cxbladder through the public healthcare system, while all residents have the option to purchase the test online.

The company continues to focus on expanding adoption through additional clinical studies aimed at generating further utility evidence and supporting physician uptake.

Investors Focus on Potential Reimbursement Expansion

Today’s share price rally suggests investors responded positively to the proposed Medicare coverage pathway and its possible implications for Pacific Edge’s commercial outlook.

While the LCD remains in draft form, the inclusion of both Cxbladder Triage and Triage Plus as proposed reimbursable tests appears to represent a significant development for the company’s US market strategy.

With reimbursement clarity potentially improving, market attention is likely to remain focused on the public consultation process, future Medicare decisions and broader commercial adoption opportunities linked to Pacific Edge’s diagnostic portfolio.